Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03737643 · ClinicalTrials.gov registry record · Phase 3

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

A Phase 3 study of Advanced Ovarian Cancer, sponsored by AstraZeneca.

Active
Registry status
Phase 3
Development phase
1,407
Enrollment target
20
Study locations

NCT03737643 is a Phase 3 study of Advanced Ovarian Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 1,407 participants, above the 241-participant average among 3 other Advanced Ovarian Cancer trials with a reported enrollment target (484% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03737643, a Phase 3 study of Advanced Ovarian Cancer, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
1,407 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.

Conditions Studied

Advanced Ovarian Cancer

Interventions

  • DRUG Bevacizumab
  • DRUG Olaparib
  • DRUG Durvalumab
  • DRUG Placebo olaparib
  • DRUG Durvalumab placebo

Study Locations (20)

California

  • Research Site - Foothill Ranch
  • Research Site - Los Angeles
  • Research Site - Orange
  • Research Site - San Francisco

New York

  • Research Site - Albany
  • Research Site - New York
  • Research Site - Uniondale

Ohio

  • Research Site - Cleveland
  • Research Site - Dayton
  • Research Site - Hilliard

New Jersey

  • Research Site - Middletown
  • Research Site - Montvale

Florida

  • Research Site - Tampa

Georgia

  • Research Site - Augusta

Illinois

  • Research Site - Hinsdale

Indiana

  • Research Site - Indianapolis

Trial Details

FieldValue
Enrollment Target 1,407 participants
Start Date 2019-01-04
Est. Completion 2028-03-30
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03737643

The ClinicalTrials.gov registry entry for NCT03737643 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,407 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 241-participant average among 3 other Advanced Ovarian Cancer trials with a reported enrollment target (484% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.

NCT03737643 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, New York, Ohio.

Frequently Asked Questions

What is clinical trial NCT03737643 about?

NCT03737643 is a clinical study titled "Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients". This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients w...

What is the current status of trial NCT03737643?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,407 participants. The study started on 2019-01-04. Estimated completion is 2028-03-30.

What conditions does trial NCT03737643 study?

This clinical trial studies the following conditions: Advanced Ovarian Cancer.

What interventions are being tested in trial NCT03737643?

The interventions under investigation include: Bevacizumab (DRUG), Olaparib (DRUG), Durvalumab (DRUG), Placebo olaparib (DRUG), Durvalumab placebo (DRUG).

Who is sponsoring clinical trial NCT03737643?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03737643 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Ovarian Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.